Skip to main
EOLS

Evolus (EOLS) Stock Forecast & Price Target

Evolus (EOLS) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Evolus is well-positioned in the growing medical aesthetics market with its two commercially available products and a strong pipeline, including the first liquid-formulation toxin. The company is also expanding globally, increasing its potential market reach. Management's positive outlook on the neurotoxin market and the tailwinds of facial volume loss in the HA gel market further support the positive outlook. The company's strong balance sheet with access to additional funding also provides financial stability for future growth.

Bears say

Evolus is facing several challenges that warrant a negative outlook, including slower-than-expected market growth for its injectables and competition from established brands like Voluma. There are also concerns about the company's ability to meet its revenue guidance and sustain profitability in the long term, as well as potential risks related to consumer spending, commercial execution, and regulatory delays. Furthermore, the company's recent price target downgrade highlights investor skepticism about its future earnings potential and market differentiation.

Evolus (EOLS) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolus (EOLS) Forecast

Analysts have given Evolus (EOLS) a Buy based on their latest research and market trends.

According to 5 analysts, Evolus (EOLS) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolus (EOLS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.